Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Merck & Company 126 East Lincoln Avenue Rahway NJ 07065 USA

www.merck.com Employees: 75,000 P: 732-594-4000

Sector:

Medical

Description:

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Key Statistics

Overview:

Market Capitalization, $K 201,284,256
Enterprise Value, $K 222,504,256
Shares Outstanding, K 2,511,031
Annual Sales, $ 64,168 M
Annual Net Income, $ 17,117 M
Last Quarter Sales, $ 15,529 M
Last Quarter Net Income, $ 5,079 M
EBIT, $ 20,398 M
EBITDA, $ 24,897 M
60-Month Beta 0.38
% of Insider Shareholders 0.09%
% of Institutional Shareholders 76.07%
Float, K 2,508,771
% Float 99.91%
Short Volume Ratio 0.46

Growth:

1-Year Return -39.59%
3-Year Return -13.27%
5-Year Return 1.75%
5-Year Revenue Growth 36.99%
5-Year Earnings Growth 47.40%
5-Year Dividend Growth 38.05%

Per-Share Information:

Most Recent Earnings 2.22 on 04/24/25
Next Earnings Date 07/29/25
Earnings Per Share ttm 7.79
EPS Growth vs. Prev Qtr 29.07%
EPS Growth vs. Prev Year 7.25%
Annual Dividend Rate, $ 3.20
Annual Dividend Yield 3.99%
Most Recent Dividend 0.810 on 06/16/25
Next Ex-Dividends Date 06/15/25
Dividend Payable Date 07/08/25
Dividend Payout Ratio 40.41%
Most Recent Split 2-1 on 02/17/99

MRK Ratios

Ratio
Price/Earnings ttm 10.15
Price/Earnings forward 8.86
Price/Earnings to Growth 0.82
Return-on-Equity % 43.23%
Return-on-Assets % 17.11%
Profit Margin % 26.68%
Debt/Equity 0.69
Price/Sales 3.09
Price/Cash Flow 8.35
Price/Book 4.12
Book Value/Share 19.19
Interest Coverage 2.84

MRK Dividends

Date Value
06/16/25 $0.8100
06/15/25 $0.8100
03/17/25 $0.8100
12/16/24 $0.8100
09/16/24 $0.7700
06/17/24 $0.7700
03/14/24 $0.7700
12/14/23 $0.7700
09/14/23 $0.7300
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar